Doctors at Queen Mary University of London, Barts Health NHS Trust, and University College London have led the development of ...
Until now, the only effective cure for primary aldosteronism has been surgical removal of the entire adrenal gland, requiring ...
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2025 Management View CEO Dave Rosa highlighted the strong performance of the OneRF ablation system, which is the first FDA-cleared product ...
The following is a summary of “Therapeutic outcomes and safety of radiofrequency ablation for primary papillary thyroid ...
A revolutionary new treatment called Targeted Thermal Therapy (Tripel T) offers a safer, faster alternative to surgery for patients with high blood pressure caused by Primary Aldosteronism, a hormonal ...
A revolutionary new treatment called Targeted Thermal Therapy (Tripel T) offers a safer, faster alternative to surgery for ...
Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from ...
Reports Q1 product revenue $3.3M vs. $1M last year. Reports Q1 license revenue $3M vs. $0 last year. “This quarter marks the next step forward ...
NeuroOne Medical Technologies Corporation ( NASDAQ: NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback